Understand the source comparison
Peptides for Estrogen Dominance: Comparison
Thymalin Thymic restoration → Treg production → aromatase suppression 5–10 mg reconstituted, 1 mg SC daily × 10 days Subcutaneous injection −20°C before reconstitution; 2–8°C after, use within 28 days Strongest mechanistic rationale for immune-driven estrogen
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic restoration → Treg production → aromatase suppression
- 5–10 mg reconstituted, 1 mg SC daily × 10 days
- Subcutaneous injection
- −20°C before reconstitution; 2–8°C after, use within 28 days
- Strongest mechanistic rationale for immune-driven estrogen excess; requires clinical supervision for dosing cycles
- KPV 5MG
- NF-κB inhibition → reduced inflammatory cytokines and aromatase expression
- 500–1000 mcg daily
- 2–8°C post-reconstitution, 28-day stability
- Directly addresses inflammatory cascade; limited human trials but robust preclinical data
- CJC-1295/Ipamorelin
- GH secretion → IGF-1 → hepatic SHBG synthesis → reduced free estradiol
- CJC: 100–200 mcg; Ipamorelin: 200–300 mcg combined
- Subcutaneous injection before sleep
- −20°C lyophilized; 2–8°C reconstituted, 28-day use window
- Indirect mechanism through metabolic correction; requires 8–12 weeks for SHBG normalization
- Tesofensine
- Triple monoamine reuptake inhibition → visceral fat reduction → lowered aromatase substrate
- 0.25–0.5 mg daily
- Oral administration
- Room temperature stable in capsule form
- Investigational status limits access; significant weight loss correlates with estrogen reduction
- Lipo C
- Methyl donor support → COMT activity → estrogen metabolite inactivation
- 1–2 mL weekly
- Intramuscular injection
- 2–8°C; protect from light
- Adjunctive support for phase II detoxification; not a standalone intervention for dominance